Comprehensive, up-to-date, evidence-based COVID19 drug-drug interaction resource, freely available to healthcare workers, patients and researchers.

In order to address this, the Liverpool Drug Interactions website team developed this freely available drug interactions resource to provide information on the likelihood of interactions between the experimental agents used for the treatment of …

The Programme Steering Committee (PSC) provides independent expert oversight of the Liverpool Drug Interactions programme, including the web- and app-based prescribing tools for managing drug-drug interactions for HIV, hepatitis and COVID-19.

We have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19. These resources are freely available and the Liverpool Drug Interactions Group would like to encourage the dissemination (with an appropriate acknowledgement) of this drug-drug interaction information for non-commercial use.

Nov 27, 2023 · A further seventeen new comedications have been added to the interaction checker: Antibacterials: Fosfomycin Anti-diabetics: Alogliptin Antifungals: Clotrimazole (pessary, troche), Clotrimazole (topical) Cancer Therapies: Methotrexate (cancer therapy) Lipid Lowering Agents: Bempedoic acid Other: Cannabidiol, Clomifene, Fezolinetant, Misoprostol, Naftidrofuryl, Neostigmine, Orlistat, Ospemifene ...

Although no systems are completely secure, The University of Liverpool and Clubzap Ltd take appropriate technical and organisational measures to help prevent misuse, loss, destruction, or damage to your personal data.

Co-administration may increase eletriptan concentrations. Co-administration of eletriptan within at least 72 hours of Paxlovid is contraindicated due to potential for serious adverse reactions including cardiovascular and cerebrovascular events.

Coadministration of fostamatinib with ritonavir may increase fostamatinib metabolite R406 exposure resulting in dose-related adverse events such as hepatotoxicity, neutropenia, hypertension or diarrhoea. Refer to the fostamatinib SmPC for dose reduction recommendations if such events occur.

Coadministration with ritonavir decreased ethinyl estradiol AUC and Cmax by 40% and 32%. Due to reductions in ethinyl estradiol concentrations, barrier or other non-hormonal methods of contraception should be considered with concomitant ritonavir use when dosed as an antiretroviral agent or as a pharmacokinetic enhancer. Ritonavir is likely to change the uterine bleeding profile and reduce the ...